Research To Practice | Oncology Videos

Featuring a slide presentation and related discussion from Dr Debra Richardson, including the following topics: Targeting folate receptor alpha in ovarian cancer; activity, tolerability and ongoing investigation of the antibody-drug conjugate (ADC) mirvetuximab soravtansine (0:00) Other ADCs under investigation for patients with ovarian cancer (20:05) Mechanism of action and activity of upifitamab...

Featuring perspectives from Dr Nicole Lamanna and Dr William G Wierda , including the following topics: Introduction: Mentoring Fellows (0:00) Case: A woman in her mid 50s with multiple cardiovascular comorbidities and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) receives bendamustine/rituximab induction followed by venetoclax/rituximab consolidation in a clinical trial — Spencer H...

Inside the Issue: Optimizing the Management of Metastatic Pancreatic Cancer | Faculty Presentation 1: Selection and Sequencing of Therapy for Metastatic Pancreatic Cancer CME information and select publications

Optimizing the Management of Metastatic Pancreatic Cancer | Faculty Presentation 2: Current and Future Role of Biomarker-Based Decision-Making for Metastatic Pancreatic Cancer CME information and select publications

Featuring perspectives from Dr Eileen O'Reilly and Dr Zev Wainberg , including the following topics: Introduction (0:00) Selection and Sequencing of Therapy for Patients with Metastatic Pancreatic Cancer (11:42) Ongoing Clinical Trials (31:33) Current and Future Role of Biomarker-Based Decision-Making in Metastatic Pancreatic Cancer (41:04) CME information and select publications

Inside the Issue: The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma | Faculty Presentation 2: Key Data Sets with Bispecific Antibodies in Diffuse Large B-Cell Lymphoma and Other Non-Hodgkin Lymphoma Subtypes — Martin Hutchings, MD, PhD CME information and select publications    

Inside the Issue: The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma | Faculty Presentation 1: Role of Bispecific Antibody Therapy in Follicular Lymphoma — Loretta J Nastoupil, MD CME information and select publications

Featuring perspectives from Professor Martin Hutchings and Dr Loretta J Nastoupil , including the following topics: Introduction (0:00) Follicular Lymphoma (2:42) Diffuse Large B-Cell Lymphoma (35:41) CME information and select publications

Featuring perspectives from Prof Georgina Long, including the following topics: Introduction: (0:00) Journal Club with Prof Long – Part 1 (7:56) Case: A man in his mid 70s presents with bilateral painfully inflamed red ears and is diagnosed with BRAF V600E-mutated metastatic melanoma — Joanna Metzner-Sadurski, MD (27:19) Case: A man in his early 70s with past medical history of diabetes, hypertens...

Featuring perspectives from Dr Corey J Langer, Dr Ticiana Leal, Dr Karen Reckamp and Dr Jacob Sands, including the following topics: Optimal use of front-line immune checkpoint inhibition for metastatic non-small cell lung cancer (NSCLC) (00:00) Case: A man in his late 60s with NSCLC, no actionable mutations, PD-L1 20%, who received second-line datopotamab deruxtecan as part of a clinical trial (1...

Featuring perspectives from Dr Ghassan Abou-Alfa and Dr Daneng Li , including the following topics: Introduction: Etiology of Hepatocellular Carcinoma (HCC) and IO Response (0:00) First-Line Therapy for Advanced HCC — Dr Abou-Alfa (17:42) Second- and Later-Line Therapy for Advanced HCC; Emerging Considerations for Patients with Resectable HCC — Dr Li (38:12) CME information and select publications

Inside the Issue: Exploring the Current and Future Management of High-Risk, Hormone-Sensitive Nonmetastatic Prostate Cancer | Faculty Presentation: Treatment Intensification for Patients with Locally Advanced and Biochemically Recurrent Prostate Cancer — Neal D Shore, MD CME information and select publications

Featuring perspectives from Dr Neal D Shore and Dr Mary-Ellen Taplin , including the following topics: Introduction (0:00) Key Data Sets (8:18) Faculty Survey (39:50) CME information and select publications

Featuring perspectives from Dr Michael Wang , including the following topics: Algorithm for observation versus initiation of therapy for newly diagnosed mantle cell lymphoma (MCL) (0:00) First- and second-line therapy approaches for MCL (7:26) Case: A 45-year-old woman with relapsed MCL receiving acalabrutinib who develops severe headaches (10:21) Current role of ibrutinib in the treatment of MCL;...

Featuring a slide presentation and related discussion from Dr Michael Wang, including the following topics: Overview of Bruton tyrosine kinase (BTK) inhibitors and clinical data establishing the efficacy of these agents for mantle cell lymphoma (MCL) (0:00) Clinical investigation of ibrutinib in the front-line setting; results from the Phase III SHINE trial and voluntary market withdrawal of ibrut...

Featuring perspectives from Dr Richard F Riedel , including the following topics: Introduction: (0:00) Case: A woman in her late 20s with multiregimen-recurrent metastatic alveolar soft part sarcoma after treatment with multiple VEGF tyrosine kinase inhibitors and a single-agent PD-1 inhibitor receives axitinib/pembrolizumab — Nam Bui, MD (4:14) Case: A man in his mid 60s with metastatic dediffere...

Featuring an interview with Dr Jeremy Abramson , including the following topics: Choice of Bruton tyrosine kinase (BTK) inhibitor as first-line therapy for chronic lymphocytic leukemia (CLL) (0:00) Perspectives on the use of chemoimmunotherapy versus BTK inhibitors as front-line treatment for CLL (2:31) Chimeric antigen receptor (CAR) T-cell therapy-associated ICANS (immune effector cell-associate...

Featuring a slide presentation and related discussion from Dr Jeremy Abramson, including the following topics: Long-term follow-up data with Bruton tyrosine kinase (BTK) inhibitors as monotherapy for chronic lymphocytic leukemia (CLL): The CLL12 and SEQUOIA trials (0:00) Extended follow-up results with venetoclax combined with anti-CD20 antibodies or a BTK inhibitor for CLL: The CLL14, MURANO and...

Featuring an interview with Dr Rana R McKay , including the following topics: Prostate Cancer (0:00) Renal Cell Carcinoma (22:58) Urothelial Bladder Cancer (52:18) CME information and select publications

Featuring perspectives from Dr Adiyta Bardia and Dr Erika Hamilton , including the following topics: Introduction: Biopharmacology and Endocrinology of Breast Cancer (0:00) Current Strategies for Previously Treated ER-Positive Metastatic Breast Cancer (mBC) — Dr Bardia (12:15) Future Directions in the Management of ER-Positive mBC — Dr Hamilton (33:16) Clinical Investigator Survey (51:50) CME info...

Inside the Issue: Current and Future Management of ER-Positive Metastatic Breast Cancer After Disease Progression on a CDK4/6 Inhibitor | Faculty Presentation 2: Future Directions in the Management of ER-Positive mBC — Erika Hamilton, MD CME information and select publications

Inside the Issue: Current and Future Management of ER-Positive Metastatic Breast Cancer After Disease Progression on a CDK4/6 Inhibitor | Faculty Presentation 1: Current Strategies for Previously Treated ER-Positive Metastatic Breast Cancer (mBC) — Aditya Bardia, MD, MPH CME information and select publications

Featuring perspectives from Dr Hans Lee and Dr Saad Zafar Usmani , including the following topics: Introduction (0:00) Biology/Immunology; Overview (3:05) Current Available Data (19:40) Clinical Investigator Survey (33:11) Combinations/Ongoing Trials (55:40) CME information and select publications

Inside the Issue: Integrating Bispecific Antibodies into the Management of Multiple Myeloma — Patient Selection and Toxicity Management | Faculty Presentation 1: Available Data with and Potential Clinical Role of Bispecific Antibodies for Multiple Myeloma (MM) CME information and select publications

Inside the Issue: Integrating Bispecific Antibodies into the Management of Multiple Myeloma — Patient Selection and Toxicity Management | Faculty Presentation 2: Tolerability and Other Practical Considerations with Bispecific Antibodies for MM CME information and select publications